Ma Y et al., 2017-10-24: Network meta-analysis of 23 trials (10,684 patients) finding PSK with chemotherapy improved 1-7 year overall and disease-free survival in gastrointestinal cancer without added side effects.
The adjuvant immunochemotherapy agent PSK is effective and safe for patients with GIC. PSK combined with chemotherapy appears to be the preferred application of PSK.
Abstract, Conclusions
Ma Y et al., 2017-10-24: Network meta-analysis of 23 trials (10,684 patients) finding PSK with chemotherapy improved 1-7 year overall and disease-free survival in gastrointestinal cancer without added side effects. Pooled largely from Japanese and Chinese trials of variable quality. Authors declare no competing interest; funder not stated. Comparator: chemotherapy alone or surgery alone across arms. Study type: review.
